DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR D-TRYPTOPHAN

« Back to Dashboard

Clinical Trials for D-Tryptophan

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00066690	Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer	Active, not recruiting	Breast International Group	Phase 3	RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
NCT00066690	Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer	Active, not recruiting	Cancer and Leukemia Group B	Phase 3	RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
NCT00066690	Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
NCT00066690	Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer	Active, not recruiting	NCIC Clinical Trials Group	Phase 3	RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
NCT00066690	Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer	Active, not recruiting	North Central Cancer Treatment Group	Phase 3	RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

Clinical Trial Conditions for D-Tryptophan

Condition Name

Condition Name for
Intervention	Trials
Unspecified Adult Solid Tumor, Protocol Specific	3
Stage IVA Prostate Cancer AJCC v8	2
Malignant Brain Tumor	2
Gliosarcoma	2

Condition MeSH

Condition MeSH for
Intervention	Trials
Breast Neoplasms	4
Prostatic Neoplasms	4
Adenocarcinoma	3
Pancreatic Neoplasms	3

Clinical Trial Locations for D-Tryptophan

Trials by Country

Trials by Country for
Location	Trials
United States	101
Canada	7
Switzerland	1
Poland	1

Trials by US State

Trials by US State for
Location	Trials
Georgia	7
Florida	6
Pennsylvania	5
Virginia	5
California	4

Clinical Trial Progress for D-Tryptophan

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	2
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Recruiting	6
Active, not recruiting	3
Not yet recruiting	3

Clinical Trial Sponsors for D-Tryptophan

Sponsor Name

Sponsor Name for
Sponsor	Trials
National Cancer Institute (NCI)	8
NewLink Genetics Corporation	6
Southwest Oncology Group	2

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	14
NIH	8
Industry	7